Tiger BioSciences’ recap of 2025’s major milestones

Recap

Tiger BioSciences spotlights the number of important and valuable scientific and clinical advances that have been made from the company’s extensive investment in proof-based research across this year. This smart and rock-built strategy target has bolstered the company’s position as a market champion, now stepping into 2026 with more confidence and a promising portfolio defining clinical validation, scientific eviodence and data.

This year, Tiger BioSciences created and backed five peer-validate restrospective clinical studies, among which two concentrated on the company’s leading completeFT product. These studies emphasise the product’s positive impact in modern wound management and have developed a new, different role as a convincing solution provider for clinicians globally.

Tiger have also upgraded its commitment level to provide a high quality proved solution via a prospective, robust randomised controlled trial (RCT) assessing the implementation of caregraFT for venous leg ulcers and diabetic foot ulcers. The primitive findings from this running RCT confirm excellent clinical outcomes that reinforce the ability of caregraFT as a future alternative for chronic wound care.

President of Tiger Wound Care, Garrett Grinsfelder, said, “We feel that significant clinical proof is the ground of the long-standing innovation in wound care. Our research investment in 2025 mirrors our dedication to data and serving trustworthy products to the clinicians.”

Plans

Tiger BioSciences will further extend its clinical research program along with the RCT assessing caregraFT’s positive impact in pressure ulcer care. Grinsfelder added, “With various completed manuscripts and peer-reviewed studies and two attentive RCTs on the way in 2026, the company has earned the position as a market champion. The market champion with the products supported by the comprehensive scientific and clinical data. We are grateful for this successful 2025 and are further thrilled for the research’s effectiveness we will be achieving in patient care.”

The company, being a tissue recovery agency, a marketing partner to clinicians, an innovator and a loyal part of the donor, patients and provider group, is promising to offer the best of 2026. The ongoing RCT sheds light on the development of some promising solutions that will be driving improvement in the venous leg ulcers and diabetic foot ulcers condition.

This recap is a tribute to the valuable decisions, advancement and progress the company has made in 2025. Furthermore, Tiger BioSciences has some plans and next-generation advancements stored in their resolution list to meet satisfactory results in the company’s business wavelength.